» Articles » PMID: 36105390

An Investigation of the Conformity, Feasibility, and Expected Clinical Benefits of Multiparametric MRI-guided Dose Painting Radiotherapy in Glioblastoma

Overview
Journal Neurooncol Adv
Date 2022 Sep 15
PMID 36105390
Authors
Affiliations
Soon will be listed here.
Abstract

Background: New technologies developed to improve survival outcomes for glioblastoma (GBM) continue to have limited success. Recently, image-guided dose painting (DP) radiotherapy has emerged as a promising strategy to increase local control rates. In this study, we evaluate the practical application of a multiparametric MRI model of glioma infiltration for DP radiotherapy in GBM by measuring its conformity, feasibility, and expected clinical benefits against standard of care treatment.

Methods: Maps of tumor probability were generated from perfusion/diffusion MRI data from 17 GBM patients via a previously developed model of GBM infiltration. Prescriptions for DP were linearly derived from tumor probability maps and used to develop dose optimized treatment plans. Conformity of DP plans to dose prescriptions was measured via a quality factor. Feasibility of DP plans was evaluated by dose metrics to target volumes and critical brain structures. Expected clinical benefit of DP plans was assessed by tumor control probability. The DP plans were compared to standard radiotherapy plans.

Results: The conformity of the DP plans was >90%. Compared to the standard plans, DP (1) did not affect dose delivered to organs at risk; (2) increased mean and maximum dose and improved minimum dose coverage for the target volumes; (3) reduced minimum dose within the radiotherapy treatment margins; (4) improved local tumor control probability within the target volumes for all patients.

Conclusions: A multiparametric MRI model of GBM infiltration can enable conformal, feasible, and potentially beneficial dose painting radiotherapy plans.

Citing Articles

Prediction of radiologic outcome-optimized dose plans and post-treatment magnetic resonance images: A proof-of-concept study in breast cancer brain metastases treated with stereotactic radiosurgery.

Pandey S, Kutuk T, Abdalah M, Stringfield O, Ravi H, Mills M Phys Imaging Radiat Oncol. 2024; 31:100602.

PMID: 39040435 PMC: 11261135. DOI: 10.1016/j.phro.2024.100602.

References
1.
Kim M, Aryal M, Sun Y, Parmar H, Li P, Schipper M . Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma. Neuro Oncol. 2021; 23(9):1537-1546. PMC: 8408852. DOI: 10.1093/neuonc/noab038. View

2.
Jiang H, Yu K, Li M, Cui Y, Ren X, Yang C . Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications. Front Oncol. 2020; 10:590648. PMC: 7673412. DOI: 10.3389/fonc.2020.590648. View

3.
Tsien C, Moughan J, Michalski J, Gilbert M, Purdy J, Simpson J . Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys. 2008; 73(3):699-708. PMC: 2913423. DOI: 10.1016/j.ijrobp.2008.05.034. View

4.
Smith S . Fast robust automated brain extraction. Hum Brain Mapp. 2002; 17(3):143-55. PMC: 6871816. DOI: 10.1002/hbm.10062. View

5.
Wen P, Weller M, Quant Lee E, Alexander B, Barnholtz-Sloan J, Barthel F . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020; 22(8):1073-1113. PMC: 7594557. DOI: 10.1093/neuonc/noaa106. View